Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. Abattis follows strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
Abattis Bioceuticals Corp. (ATT)
March 3, 2017
Effective immediately the shares of Abattis Bioceuticals Corp. will be reinstated for trading.
The Company has rectified the default situation that gave rise to the suspension.
Effective Date: March 3, 2017
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com